Old Articles: <Older 8521-8530 Newer> |
|
Chemistry World February 7, 2013 Maria Burke |
GSK commits to AllTrials data disclosure GlaxoSmithKline has become the first pharmaceutical company to sign up to a high-profile campaign to make detailed data on all clinical trials available to the public. |
Chemistry World February 1, 2013 Andrew Turley |
Zoetis IPO launches at $2.2bn The separation of Pfizer from its animal health business, Zoetis, has begun. Pfizer has priced its initial public offering of 86 million shares at $26 per share, for a total of $2.2 billion |
Pharmaceutical Executive January 1, 2013 Ben Comer |
Compliance in the C-Suite Compliance officers have risen into pharmaceutical management's highest ranks, by choice in some organizations, and by government decree in others. Either way, their importance as a strategic partner can hardly be understated. |
Pharmaceutical Executive January 1, 2013 |
Product Liability Claims and Comment K Courts across the country are making it easier to prove that a drug is unsafe, warning label notwithstanding. |
Chemistry World January 25, 2013 Andrew Turley |
Allergan buys MAP for $958m Allergan, best known as the company behind Botox (onabotulinumtoxin A) injections, has agreed to buy US drug maker MAP Pharmaceuticals for $958 million |
Chemistry World January 25, 2013 Rajesh Parishwad |
Indian supreme court's anger over unregulated clinical trials The fledgling clinical trials industry in India has been hit by recent revelations of a lack of regulation. Now, the country's supreme court has criticized the body that oversees clinical trials for its inaction in the face of these unethical practices. |
Pharmaceutical Executive January 25, 2013 William Looney |
Industry Forecast 2013 As companies seek safety from empowered payers, restive patients, bankrupt governments, and distracted regulators, success will come to those who understand how competition and technology are changing the way everything this industry does. |
Chemistry World January 24, 2013 Andrew Turley |
Vasella to leave Novartis in August Veteran pharma executive Danial Vasella has unexpectedly announced his resignation as chair of the board of directors at Novartis after 17 years at the top of the company. |
Pharmaceutical Executive January 1, 2013 William Looney |
The Permanent Campaign Promoting the merits of private-sector drug innovation is no easy task; just ask the UK's Office of Health Economics, with a record 50 years of engagement around the hard policy questions that ultimately drive success in the pharmaceutical marketplace. |
Pharmaceutical Executive January 1, 2013 Kenneth Getz |
The Scoop on Drug Shortages New research sheds fresh light on a trend with serious consequences for the public health; not only in the United States but for patients worldwide. |
<Older 8521-8530 Newer> Return to current articles. |